In our March issue: FEATURES Cover Story 23andMe's Double Play: Making Science and Patients Partners Casey McDonald
Pharm Exec's Casey McDonald profiles patient DNA partnering advocate 23andMe, which recently struck data deals with a pair of big Pharmas, thrusting the debate over personal genomics and patient treatment back into high gear.
Biotech Behind the Boom in Biotech William Looney
On the margins of January's annual JP Morgan investorfest, Pharm Exec convened a roundtable discussion with nine company aspirants for leadership in the hard science of small biotech.
Emerging Markets BioScience Bounty: Africa's Emerging Geography of Ideas William Looney Pfizer recently hosted a delegation of start-up entrepreneurs and R&D “incubator” executives with the aim to identify actions to break the logjams around great science through a sustainable network of private-sector bioscience enterprises — particularly in emerging market countries like South Africa, where useful precedents exist on delivering health innovations at lower cost to society
Sales Tomorrow's Selling Strategy: Test and Invest Rick Edmunds, Rolf Fricker, Stephan Danner, Nelia Padilla
A new PwC survey reveals a strong need to fully embrace alternative commercial methods—not in a blind frenzy but through careful evaluation of which new sales strategies have true innovative potential.
ALSO IN THIS ISSUE Is There Gold in the DNA Selfie? William Looney
Pharma jumps on board personal genomics train—at least for test drive—but will journey ultimately help transform treatment or stall out as just another fad?
Pharma's Love Affair with Buzzwords Timothy White
How pharma can finally put true meaning behind its juiced-up jargon and turn the bluster into reality.